Amsterdam, the Netherlands – Findings from a new study in the Journal of Neuromuscular Diseases, published by IOS Press, demonstrate the effectiveness of disease-modifying treatments (DMTs) in infants with spinal muscular atrophy (SMA). The study's results add further support for gene therapy as a treatment modality that can deliver durable transformative effects for these vulnerable patients.
SMA is a rare, debilitating neuromuscular disease characterized by loss of motor neurons, leading to progressive weakness and atrophy of skeletal and bulbar muscles. It has long been cited as the leading genetic cause of infant mortality, caused by the deletion or mutation of the survival motor neuron 1 (SMN1) gene. However, prognoses have improved markedly in recent years, mainly owing to the advent of DMTs. Knowledge of these new treatments for SMA has been largely based on interventional trial data, which is limited by narrow eligibility criteria and limited follow-up duration. In this new study, real-world effectiveness and safety outcomes were assessed for patients following onasemnogene abeparvovec monotherapy, a gene therapy that replaces the missing SMN1 gene.
"When planning to deliver a gene therapy to an infant with SMA, we need to be able to give evidence-based answers to parents' questions. They want to know what the risks are as well as the chances for a child to be able to walk, sit, or be independent of ventilation within several years," explains lead investigator Laurent Servais, MD, PhD, MDUK Oxford Neuromuscular Centre & NIHR Oxford Biomedical Research Centre, University of Oxford; and Neuromuscular Reference Center, Department of Paediatrics, University and University Hospital of Liège.
He adds, "Real-world data, i.e., data collected after approval in actual clinical use, has been crucial for filling knowledge gaps and demonstrating through clinical experience that onasemnogene abeparvovec is associated with improvements in motor function, bulbar function, and pulmonary function in a varied SMA patient population and over an extended period of observation."
Although almost all cases of SMA have the same underlying genetic cause — a biallelic deletion or mutation in the SMN1 gene — clinical severity is heterogeneous, with varying copy number of the SMN2 “backup” gene being strongly correlated with disease onset and severity as an important phenotypic modifier of SMA.
Using data on 168 patients from RESTORE, a prospective, multicenter, multinational, observational registry that captures data from a variety of sources, investigators identified 80 patients (47.6%) with two and 70 (41.7%) with three copies of SMN2. Ninety-eight (58.3%) identified by newborn screening (NBS) had a lower age at final assessment (mean age 11.5 months) and greater mean final score on the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND), compared with clinically diagnosed patients. All patients maintained and/or achieved motor milestones, such as sitting without support for 10 seconds, crawling, and walking. Observed adverse events were consistent with the established safety profile of onasemnogene abeparvovec.
Because RESTORE provides data from a large SMA population, it can facilitate studying specific subgroups and providing answers to specific questions like what happens to patients with one copy of SMN2 and what is the benefit for patients on permanent ventilation.
"Another key finding from this study was the improved safety profile demonstrated for infants identified by NBS. Our data confirm other real-world and clinical study data that infants identified by NBS are diagnosed and assessed earlier and had a tendency for better outcomes when treated. This provides evidence to demonstrate that the early treatment opportunity offered by NBS can be transformative for patients," Dr. Servais observes.
# # #
NOTES FOR EDITORS
“Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry,” by Laurent Servais, John W. Day, Darryl C. De Vivo, Janbernd Kirschner, Eugenio Mercuri, Francesco Muntoni, Crystal M. Proud, Perry B. Shieh, Eduardo F. Tizzano, Susana Quijano-Roy, Isabelle Desguerre, Kayoko Saito, Eric Faulkner, Kamal M. Benguerba, Dheeraj Raju, Nicole LaMarca, Rui Sun, Frederick A. Anderson, and Richard S. Finkel (https://doi.org/10.3233/JND-230122), Journal of Neuromuscular Diseases, Volume 11, issue 2. The article is openly available at https://content.iospress.com/articles/journal-of-neuromuscular-diseases/jnd230122.
Full text of this paper is also available to credentialed journalists upon request. Please contact Diana Murray, IOS Press, at +1 718-640-5678 or d.murray@iospress.com for the full text of the article or additional information. Journalists who wish to interview the authors should contact Laurent Servais, MD, PhD, at laurent.servais@paediatrics.ox.ac.uk.
All financial and material support for this research was provided by Novartis Gene Therapies, Inc.
ABOUT THE JOURNAL OF NEUROMUSCULAR DISEASES (JND)
The Journal of Neuromuscular Diseases facilitates progress in understanding the molecular genetics/correlates, pathogenesis, pharmacology, diagnosis, and treatment of acquired and genetic neuromuscular diseases (including muscular dystrophy, myasthenia gravis, spinal muscular atrophy, neuropathies, myopathies, myotonias, and myositis). The journal publishes research reports, reviews, and short communications. Guided by Editors-in-Chief Carsten G. Bönnemann (National Institute of Neurological Disorders and Stroke, NIH) and Hanns Lochmüller (Children’s Hospital of Eastern Ontario Research Institute), the journal is dedicated to providing an open forum for original research in basic science, translational, and clinical research that will improve our fundamental understanding and lead to effective treatments of neuromuscular diseases. www.iospress.com/journal-of-neuromuscular-diseases
ABOUT IOS PRESS
IOS Press, now part of Sage, is an international scientific, technical, medical (STM) publishing house established in 1987 in Amsterdam. We produce around 90 journals and 70 books annually in a broad range of subject categories, primarily specializing in health and life sciences (including neurosciences, medical informatics, cancer research, and rehabilitation) and computer sciences (including artificial intelligence, data science, and semantic web). In addition, we offer specialized services that support scientific advancement. www.iospress.com
ABOUT SAGE
Sage is a global academic publisher of books, journals, and library resources with a growing range of technologies to enable discovery, access, and engagement. Believing that research and education are critical in shaping society, 24-year-old Sara Miller McCune founded Sage in 1965. Today, we are controlled by a group of trustees charged with maintaining our independence and mission indefinitely. https://group.sagepub.com
As part of its commitment to represent researchers from all parts of the world, the Journal of Alzheimer's Disease (JAD) is pleased to announce active outreach...
Ryan Andrew Mace, PhD, an investigator in the Center for Health Outcomes and Interdisciplinary Research (CHOIR) within the department of Psychiatry at...
Amsterdam, the Netherlands – A pilot study using a new screening tool shows promise for assessing neurobehavioral difficulties in children with Duchenne...
